Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells
This joint proof-of-concept study will initially seek to determine whether CTCs from lung cancers provide microRNA signatures similar to those previously demonstrated by
The goal of this project is to demonstrate proof-of-concept and determine opportunities for next steps in development of advanced diagnostics. This could include the development of next generation versions of certain current tests, which would then use CTCs from blood as "liquid biopsies" in lieu of current invasive approaches. With proof-of-concept data, the joint platform could be of value to pharmaceutical and biotech companies searching for a way to use liquid biopsies/CTCs along with microRNA profiling (and other downstream modalities like Next Generation Sequencing mutational profiles) to predict and monitor response to therapies.
"Our ability to capture and release CTCs for further downstream analysis puts us in a unique position to partner with leading companies who have already developed proprietary biomarker signatures," said
Analysis of CTCs provides the ability to obtain genomic information from patients where tissue biopsies are not practical or possible. A simple blood draw allows the study of tumor cells in circulation on a real-time basis starting with the point-of-diagnosis and continuing throughout treatment. For example, this provides valuable insights when a patient's disease progresses while on therapy due to emerging resistance, thus allowing the clinician to potentially plot the optimal next course of treatment. MicroRNA analysis can provide unique insight into the biomarker profiles of these cells. Combining current and new microRNA profiles through the use of CTC capture could expand the role and utility of microRNA signatures in various solid tumor diseases.
"By combining our existing expertise in the microRNA space with
About
About
Founded in 2000,
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although
CONTACT: Company Contacts:Source:Rosetta Genomics Ken Berlin , President & CEO (609) 419-9003 investors@rosettagenomics.com LHA Anne Marie Fields 212-838-3777 afields@lhai.comBiocept, Inc. David Burke The Ruth Group 646-536-7009 dburke@theruthgroup.com
News Provided by Acquire Media